For our Friday File fun today I’ve got a couple udpated thoughts and check-ins on some companies that I follow and have written to you about before, but I also always like to toss in a teaser solution as we go along — so first we’ll have a look at the latest pitch from Keith […]
Articles
We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.
More Info
Comments
You are correct about MSCI which is going through its third stage of inception and increased inclusion of China large ca...
True, the home listing is in Hong Kong at ticker 6160, where the price is about HK$117 as of the last close -- at the la...
The second biotech appears to be Ascletis Pharma (1672.HK) which was the first biotech to list on the HK exchange under ...
Also Amgen has taken a stake in Beigene at a premium which caused the latest sharp price increase at the end of October....
I would tend to agree... though one substantial beneficiary of any real capital flight from Hong Kong, assuming that the...
Friday: Build King up 8.59% to HK$ 1.27...
Fidelity and Ameritrade don't by default offer direct international trading online, you might have to call them if you w...
I bought in October last year after Tycango first wrote it up in May or June. Build King has doubled since then. The ord...